NS101 Phase 1b/2a Clinical Trial IND Approval by MFDS

Selected as KDDF National New Drug Development Project

Bridge funding (KRW 7.6 billion)

NS101 Clinical Trial Phase 2a initiation (indication: sudden sensorineural hearing loss)

Phase 1a Clinical Trial Completed in Canada

Selected as a Super-Gap Startup Project by the Ministry of SMEs and Startups

Received Minister's Award from the Ministry of Trade, Industry and Energy on the 58th Invention Day

Passed Korean Exchange’s Technology Assessment for KOSDAQ Market Listing

Certified as an excellent company for job inventions by Korean Intellectual Property Office

Certified as an intellectual property management company by Korean Intellectual Property Office

NET New Technology Certification by Ministry of Trade, Industry and Energy

Pre-IPO funding (KRW 8.6 billion)

Received Minister's Award for Excellent R&D Company in Bio-Health Sector from Ministry of Trade, Industry and Energy

NS101 Phase 1a Clinical Trial IND Approval by Health Canada

Series C funding (KRW 35 billion)

Received the Prime Minister's Award at the Republic of Korea Invention and Patent Exhibition

Series B funding (KRW 10 billion)

Establishment of Neuracle Genetics Co., Ltd. as a subsidiary

Signed a licensing agreement with Reyon Pharmaceutical Co., Ltd.

Selected as a Promising Bio IP Project by the Ministry of Trade, Industry and Energy (KRW 4 billion)

Certified as a venture company

Series A funding (KRW 4.24 billion)

Establishment of Neuracle Science Co., Ltd.

Research center confirmed for the company affiliation